Bpifrance grants Nanobiotix a 2MEU interest-free loan to support final development stage of lead product, NBTXR3 PARIS, Sept. 19, 2016 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer,...

NANOBIOTIX: starts Phase I/II clinical trial in liver Metastasis and Hepatocellular Cancer with its lead product NBTXR3 PARIS, July 1, 2015 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO), a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, has been authorized to...

NANOBIOTIX: sees Clinical Advance in Soft Tissue Sarcoma Pilot Trial with Lead Product, NBTXR3 Market Development Plan Outlined For Earlier Potential Launch in 2016 Small but heading for the big time PARIS, Feb. 10, 2014 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO), a clinical-stage nanomedicine company pioneering novel approaches for the local treatment...